Supplements and Featured Publications
BEST PRACTICES in Managing FGFRi Treatment–Related AEs: Intrahepatic Cholangiocarcinoma
This article is funded by Taiho Oncology, Inc. The publisher is solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this article is not medical advice, and does not replace independent medical judgment.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5